


ABSTRACT OF THE DISCLOSURE

5 Compounds of formula (I) and II) are provided



10 wherein: X is an alkali metal or a basic amine moiety; R₁ is alkyl, cycloalkyl, -CH₂-cycloalkyl, pyridinyl, -CH₂-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R₂ is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, -CH₂-cycloalkyl, -NH₂, or -NO₂; R₃ is phenyl, benzyl, benzyloxy, pyridinyl, or -CH₂-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.

15

20